Compile Data Set for Download or QSAR
maximum 50k data
Found 76 Enz. Inhib. hit(s) with all data for entry = 8216
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237018(US9388197, 20)
Affinity DataIC50:  1.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237032(US9388197, 34)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237039(US9388197, 41)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237060(US9388197, 62)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237065(US9388197, 67)
Affinity DataIC50:  2.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237063(US9388197, 65)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237025(US9388197, 27)
Affinity DataIC50:  3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237072(US9388197, 74)
Affinity DataIC50:  3.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237009(US9388197, 11)
Affinity DataIC50:  4.10nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237058(US9388197, 60)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237066(US9388197, 68)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237004(US9388197, 6)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237017(US9388197, 19)
Affinity DataIC50:  4.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237026(US9388197, 28)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237057(US9388197, 59)
Affinity DataIC50:  4.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237038(US9388197, 40)
Affinity DataIC50:  5.20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237023(US9388197, 25)
Affinity DataIC50:  6.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237054(US9388197, 56)
Affinity DataIC50:  6.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237040(US9388197, 42)
Affinity DataIC50:  6.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237003(US9388197, 5)
Affinity DataIC50:  7.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237046(US9388197, 48)
Affinity DataIC50:  7.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237050(US9388197, 52)
Affinity DataIC50:  7.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237052(US9388197, 54)
Affinity DataIC50:  8.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237015(US9388197, 17)
Affinity DataIC50:  11nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237059(US9388197, 61)
Affinity DataIC50:  12nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237008(US9388197, 10)
Affinity DataIC50:  12nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237051(US9388197, 53)
Affinity DataIC50:  13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237010(US9388197, 12)
Affinity DataIC50:  13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237071(US9388197, 73)
Affinity DataIC50:  13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237064(US9388197, 66)
Affinity DataIC50:  13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237013(US9388197, 15)
Affinity DataIC50:  15nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237011(US9388197, 13)
Affinity DataIC50:  17nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237048(US9388197, 50)
Affinity DataIC50:  20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237061(US9388197, 63)
Affinity DataIC50:  20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237029(US9388197, 31)
Affinity DataIC50:  22nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237049(US9388197, 51)
Affinity DataIC50:  23nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237047(US9388197, 49)
Affinity DataIC50:  25nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237056(US9388197, 58)
Affinity DataIC50:  31nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237070(US9388197, 72)
Affinity DataIC50:  36nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237012(US9388197, 14)
Affinity DataIC50:  38nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237031(US9388197, 33)
Affinity DataIC50:  44nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237024(US9388197, 26)
Affinity DataIC50:  49nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237041(US9388197, 43)
Affinity DataIC50:  53nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237016(US9388197, 18)
Affinity DataIC50:  66nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237034(US9388197, 36)
Affinity DataIC50:  71nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237030(US9388197, 32)
Affinity DataIC50:  76nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237073(US9388197, 75 | US9388197, 76)
Affinity DataIC50:  82nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237020(US9388197, 22)
Affinity DataIC50:  85nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237022(US9388197, 24)
Affinity DataIC50:  92nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237069(US9388197, 71)
Affinity DataIC50:  94nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 76 total ) | Next | Last >>
Jump to: